Background: Selective inhibition of cyclooxygenase-2 (COX-2) reduces the production of prostaglandin E2 (PGE2), which can have both pro- and anti-inflammatory effects on allergic inflammation. Moreover, in vitro PGE2 has been shown to affect inflammation through the modulation of lymphocyte responses. Methods: Sixteen subjects with mild allergic asthma were recruited to a two-period cross-over study: one treatment period with the selective COX-2 inhibitor etoricoxib and one without. Each treatment period ended with an airway challenge with the patient's relevant allergen. Antigen-specific proliferation with the major cat allergen, Fel d 1, was analysed in PBMCs. CD4+ T cells were phenotyped using flow cytometry, and mRNA expression of FOXP3 in anti-CD3-stimulated CD4+ cells were analysed. Results: No significant impact of in vivo inhibition of COX-2 was detected on the proportion of Th1, Th2, or Treg cells in peripheral blood. Likewise, the treatment had minor effects on the stimulated expression of FOXP3 mRNA in CD4+ T cells. Proliferation of PBMCs to the major cat allergen Fel d 1 was slightly reduced by etoricoxib treatment in cat-allergic patients. Conclusions: Short-term treatment with the COX-2 inhibitor etoricoxib had a minor impact on T-cell responses, supporting its safe use also in subjects exposed to triggers of lymphocyte activation.

Keywords:
Prostaglandin E2, T cell, Lymphocytes, COX-2, Allergy, Asthma
1.
Claar D, Hartert TV, Peebles RS Jr: The role of prostaglandins in allergic lung inflammation and asthma. Expert Rev Respir Med 2015;9:55-72.
2.
Hartert TV, Dworski RT, Mellen BG, Oates JA, Murray JJ, Sheller JR: Prostaglandin E2 decreases allergen-stimulated release of prostaglandin D2 in airways of subjects with asthma. Am J Respir Crit Care Med 2000;162:637-640.
3.
Safholm J, Manson ML, Bood J, Delin I, Orre AC, Bergman P, Al-Ameri M, Dahlen SE, Adner M: Prostaglandin E inhibits mast cell-dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor. J Allergy Clin Immunol 2015;136:1232-1239.
4.
Napolitani G, Acosta-Rodriguez EV, Lanzavecchia A, Sallusto F: Prostaglandin E2 enhances Th17 responses via modulation of IL-17 and IFN-γ production by memory CD4+ T cells. Eur J Immunol 2009;39:1301-1312.
5.
Kofler DM, Marson A, Dominguez-Villar M, Xiao S, Kuchroo VK, Hafler DA: Decreased RORC-dependent silencing of prostaglandin receptor EP2 induces autoimmune Th17 cells. J Clin Invest 2014;124:2513-2522.
6.
Bao YS, Zhang P, Xie RJ, Wang M, Wang ZY, Zhou Z, Zhai WJ, Feng SZ, Han MZ: The regulation of CD4+ T cell immune responses toward Th2 cell development by prostaglandin E2. Int Immunopharmacol 2011;11:1599-1605.
7.
Baratelli F, Lin Y, Zhu L, Yang SC, Heuze-Vourc'h N, Zeng G, Reckamp K, Dohadwala M, Sharma S, Dubinett SM: Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 2005;175:1483-1490.
8.
Daham K, James A, Balgoma D, Kupczyk M, Billing B, Lindeberg A, Henriksson E, Fitzgerald GA, Wheelock C, Dahlen SE, Dahlen B: Effects of selective COX-2 inhibition on allergen-induced bronchoconstriction and airway inflammation in asthma. J Allergy Clin Immunol 2014;134:306-313.
9.
Gyllfors P, Bochenek G, Overholt J, Drupka D, Kumlin M, Sheller J, Nizankowska E, Isakson PC, Mejza F, Lefkowith JB, Dahlen SE, Szczeklik A, Murray JJ, Dahlen B: Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 2003;111:1116-1121.
10.
Grundström J, Linton L, Thunberg S, Forsslund H, Janscewska I, Befrits R, van Hage M, Gafvelin G, Eberhardson M: Altered T-regulatory cell profile in inflammatory bowel disease patients during anti-TNF treatment. Clin Exp Immunol 2012;169:137-147.
11.
Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, Sallusto F, Napolitani G: Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007;8:639-646.
12.
Thunberg S, Gafvelin G, Nord M, Gronneberg R, Grunewald J, Eklund A, van Hage M: Allergen provocation increases Th2 cytokines and FOXP3 expression in the asthmatic lung. Allergy 2010;65:311-318.
13.
Burgler S, Ouaked N, Bassin C, Basinski TM, Mantel PY, Siegmund K, Meyer N, Akdis CA, Schmidt-Weber CB: Differentiation and functional analysis of human Th17 cells. J Allergy Clin Immunol 2009;123:588-595.e1-e7.
14.
Grönlund H, Saarne T, Gafvelin G, van Hage M: The major cat allergen, Fel d 1, in diagnosis and therapy. Int Arch Allergy Immunol 2010;151:265-274.
15.
Chizzolini C, Chicheportiche R, Alvarez M, de Rham C, Roux-Lombard P, Ferrari-Lacraz S, Dayer JM: Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood 2008;112:3696-3703.
16.
Mahic M, Yaqub S, Johansson CC, Tasken K, Aandahl EM: FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol 2006;177:246-254.
17.
Okano M, Sugata Y, Fujiwara T, Matsumoto R, Nishibori M, Shimizu K, Maeda M, Kimura Y, Kariya S, Hattori H, Yokoyama M, Kino K, Nishizaki K: E prostanoid 2 (EP2)/EP4-mediated suppression of antigen-specific human T-cell responses by prostaglandin E2. Immunology 2006;118:343-352.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.